|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400090973 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-16 20:45:33 |
|
注册时间: Date of Registration: |
2024-10-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中等长度导管与 CVC 置管在脓毒症患者静脉输液治疗中的效果探究:一项随机、 单盲、对照研究 |
|
Public title: |
Efficacy of medium length catheters and CVC catheters in intravenous infusion therapy in patients with sepsis: a randomized, single-blind, controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中等长度导管与 CVC 置管在脓毒症患者静脉输液治疗中的效果探究:一项随机、 单盲、对照研究 |
|
Scientific title: |
Efficacy of medium length catheters and CVC catheters in intravenous infusion therapy in patients with sepsis: a randomized, single-blind, controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郭亚敏 |
研究负责人: |
郭亚敏 |
|
Applicant: |
Guoyamin |
Study leader: |
Guoyamin |
|
申请注册联系人电话: Applicant telephone: |
+86 159 8516 2742 |
研究负责人电话:
Study leader's |
+86 159 8516 2742 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1961231032@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1961231032@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
云岩区飞山街83号 |
研究负责人通讯地址: |
云岩区飞山街83号 |
|
Applicant address: |
The Second Affiliated Hospital of Guizhou University of Chinese Medicine |
Study leader's address: |
No.83, Feishan Street, Yunyan District |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州中医药大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Guizhou University of Chinese Medicine |
||
|
研究负责人所在单位: |
贵州中医药大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Guizhou University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY20240730 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州中医药大学第二附属医学伦理委员会 |
||
|
Name of the ethic committee: |
The Second Affiliated Medical Ethics Committee of Guizhou University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-30 00:00:00 | ||
|
伦理委员会联系人: |
马武开 |
||
|
Contact Name of the ethic committee: |
Mawukai |
||
|
伦理委员会联系地址: |
贵州中医药大学第二附属医院 |
||
|
Contact Address of the ethic committee: |
The Second Affiliated Hospital of Guizhou University of Chinese Medicine |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 139 8500 4689 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
贵州中医药大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Guizhou University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
云岩区飞山街83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.83, Feishan Street, Yunyan District |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
None |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
脓毒症 |
||||||||||||||||||||||
|
Target disease: |
Sepsis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单病例随机对照研究 |
||||||||||||||||||||||
|
Study design: |
N of 1 Trial |
||||||||||||||||||||||
|
研究目的: |
本研究主要通过探究B超引导下中等长度导管与CVC置管在脓毒症患者静脉输液治疗中的效果,为脓毒症患者在静脉输液工具中选择提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study mainly explored the effects of B-ultrasound guided medium length catheter and CVC catheterization in intravenous infusion treatment of sepsis patients, providing evidence for the selection of intravenous infusion tools for sepsis patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18岁,性别不限; (2)需要置管治疗的脓毒症患者; (3)治疗依从性较好的患者; (4)穿刺部位皮肤完好,无破溃无损伤,血管弹性较好,适宜穿刺的患者; (5)患者的实验室化验结果显示血小板及凝血功能处于正常范围的患者; (6)获取患者或家属知情同意。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Age ≥18 years old, gender unlimited; (2) Septic patients requiring catheterization; (3) Patients with good treatment compliance; (4) The skin of the puncture site is intact, without rupture or damage, and the vascular elasticity is good, which is suitable for puncture; (5) Patients whose laboratory test results show that platelet and coagulation function are in the normal range; (6) Obtain informed consent from patients or family members. |
||||||||||||||||||||||
|
排除标准: |
(1)脓毒症休克患者; (2)穿刺部位静脉血栓; (3)同侧动静脉造瘘管; (4)拟穿刺肢体部位有疼痛、感染、血管受损(静脉炎、硬化等)、计划手术或放疗; (5)上腔静脉压迫综合征; (6)肢体畸形、关节功能障碍; (7)胸廓畸形、锁骨骨折有明显的畸形愈合; (8)高凝状态病史、四肢的静脉血流降低(如麻痹、矫形); (9)乳腺手术清扫腋窝淋巴结、淋巴水肿的患者; (10)已确定或疑似有与导管相关感染形成的患者; (11)过敏体质,已确定或疑似对输液导管材料过敏的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) septic shock patients; (2) Venous thrombosis at the puncture site; (3) ipsilateral arteriovenous fistula; (4) Pain, infection, vascular damage (phlebitis, sclerosis, etc.), planned surgery or radiotherapy in the intended piercing limb; (5) superior vena cava compression syndrome; (6) Limb deformity, joint dysfunction; (7) There were obvious malunion of thoracic malformations and clavicle fractures; (8) A history of hypercoagulability, reduced venous blood flow in the extremities (e.g. paralysis, orthosis); (9) Patients with axillary lymph nodes and lymphedema undergoing breast surgery; (10) Patients with established or suspected catheter-associated infection; (11) Patients with allergies, who have been identified or suspected to be allergic to infusion catheter materials. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-08-01 00:00:00至 To 2025-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-10-18 00:00:00 至 To 2025-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
符合入组标准的脓毒症患者采用随机数字表法及随机数余数分组法进行分组,即将纳入研究的脓毒症患者进行编号,从随机数字表中任意一个数开始,沿同一方向顺序获取每个患者一个随机数字,随机数除以组数(本研究分为两组)求余数并按其分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Sepsis patients meeting the enrollment criteria were grouped by random number table method and random number remainder grouping method. Sepsis patients to be included in the study were numbered. Starting from any number in the random number table, a random number was obtained for each patient in the same direction, and the random number was divided by the number of groups (this study was divided into two groups) to obtain the remainder and group according to it. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究采用单盲设计,即研究者及研究医护知晓受试者的分组和研究置管情况,受试者因盲法的设置无法知晓自己的研究置管。 |
|
Blinding: |
This study adopted a single-blind design, that is, the researchers and study nurses knew the group of subjects and the study catheterization situation, and the subjects could not know their own study catheterization due to the blind setting. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |